• Something wrong with this record ?

Time in Therapeutic Range of Unfractionated Heparin-Based Therapy in Critically Ill Patients with COVID-19 Pneumonia

T. Romanová, F. Burša, P. Sklienka, J. Sagan, M. Vaňková, D. Buršík, M. Bílená, M. Pulcer, M. Burda, J. Máca

. 2024 ; 20 (-) : 611-618. [pub] 20240910

Status not-indexed Language English Country New Zealand

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24017850

PURPOSE: Anticoagulation therapy aims to improve the outcome of critically ill patients with severe COVID-19-associated pneumonia. Activated partial thromboplastin time (aPTT) is commonly used to maintain the target therapeutic range of continuous infusion of unfractionated heparin (UFH). The UFH infusion efficacy can be evaluated by determining the time in therapeutic range (TTR) using a modified Rosendaal method. The present study's primary aim was to evaluate TTR based on the aPTT in critically ill patients with severe forms of COVID-19 pneumonia and its influence on survival. The secondary aim was to evaluate the time spent above (TATR) and below the therapeutic range (TBTR). PATIENTS AND METHODS: We performed a retrospective analysis of critically ill patients with COVID-19-associated pneumonia. All patients received a continuous infusion of UFH from the 2nd to 8th day since admission to the ICU. TTR, TATR, and TBTR were calculated using the modified Rosendaal method, and survival days were analyzed by regression (censored after 60 days). RESULTS: Of 103 patients, the median TTR was 49% (IQR 38-63%), TATR 11% (IQR 5-20%), and TBTR 33% (IQR 22-51%). The regression analysis indicated a positive impact of higher TTR and TATR on the number of survival days [β=0.598 (p=0.0367) and β=1.032 (p=0.0208), respectively] and a negative impact of higher TBTR [β=-0.681 (p=0.0033)] on the number of survival days. CONCLUSION: Higher TTR and TATR were associated with better survival of critically ill patients with a severe course of COVID-19-associated pneumonia. Higher TBTR was associated with worse survival in these patients.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24017850
003      
CZ-PrNML
005      
20241016081848.0
007      
ta
008      
241008e20240910nz f 000 0|eng||
009      
AR
024    7_
$a 10.2147/TCRM.S476187 $2 doi
035    __
$a (PubMed)39280635
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a nz
100    1_
$a Romanová, Tereza $u Department of Anesthesiology and Intensive Care Medicine, University Hospital, Ostrava, Czech Republic $u Department of Intensive Medicine, Emergency Medicine and Forensic Studies, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0000000162228922
245    10
$a Time in Therapeutic Range of Unfractionated Heparin-Based Therapy in Critically Ill Patients with COVID-19 Pneumonia / $c T. Romanová, F. Burša, P. Sklienka, J. Sagan, M. Vaňková, D. Buršík, M. Bílená, M. Pulcer, M. Burda, J. Máca
520    9_
$a PURPOSE: Anticoagulation therapy aims to improve the outcome of critically ill patients with severe COVID-19-associated pneumonia. Activated partial thromboplastin time (aPTT) is commonly used to maintain the target therapeutic range of continuous infusion of unfractionated heparin (UFH). The UFH infusion efficacy can be evaluated by determining the time in therapeutic range (TTR) using a modified Rosendaal method. The present study's primary aim was to evaluate TTR based on the aPTT in critically ill patients with severe forms of COVID-19 pneumonia and its influence on survival. The secondary aim was to evaluate the time spent above (TATR) and below the therapeutic range (TBTR). PATIENTS AND METHODS: We performed a retrospective analysis of critically ill patients with COVID-19-associated pneumonia. All patients received a continuous infusion of UFH from the 2nd to 8th day since admission to the ICU. TTR, TATR, and TBTR were calculated using the modified Rosendaal method, and survival days were analyzed by regression (censored after 60 days). RESULTS: Of 103 patients, the median TTR was 49% (IQR 38-63%), TATR 11% (IQR 5-20%), and TBTR 33% (IQR 22-51%). The regression analysis indicated a positive impact of higher TTR and TATR on the number of survival days [β=0.598 (p=0.0367) and β=1.032 (p=0.0208), respectively] and a negative impact of higher TBTR [β=-0.681 (p=0.0033)] on the number of survival days. CONCLUSION: Higher TTR and TATR were associated with better survival of critically ill patients with a severe course of COVID-19-associated pneumonia. Higher TBTR was associated with worse survival in these patients.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Burša, Filip $u Department of Anesthesiology and Intensive Care Medicine, University Hospital, Ostrava, Czech Republic $u Department of Intensive Medicine, Emergency Medicine and Forensic Studies, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Sklienka, Peter $u Department of Anesthesiology and Intensive Care Medicine, University Hospital, Ostrava, Czech Republic $u Department of Intensive Medicine, Emergency Medicine and Forensic Studies, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Sagan, Jiří $u Department of Infectious Diseases, University Hospital Ostrava, Ostrava, Czech Republic
700    1_
$a Vaňková, Michelle $u Department of Anesthesiology and Intensive Care Medicine, University Hospital, Ostrava, Czech Republic $1 https://orcid.org/0009000597195186
700    1_
$a Buršík, Denis $u Department of Anesthesiology and Intensive Care Medicine, University Hospital, Ostrava, Czech Republic $u Department of Intensive Medicine, Emergency Medicine and Forensic Studies, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Bílená, Markéta $u Department of Anesthesiology and Intensive Care Medicine, University Hospital, Ostrava, Czech Republic $u Department of Intensive Medicine, Emergency Medicine and Forensic Studies, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Pulcer, Martin $u Institute of Laboratory Medicine, University Hospital Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0000000346375222
700    1_
$a Burda, Michal $u Institute for Research and Applications of Fuzzy Modeling, CE IT4Innovations, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Máca, Jan $u Department of Anesthesiology and Intensive Care Medicine, University Hospital, Ostrava, Czech Republic $u Department of Intensive Medicine, Emergency Medicine and Forensic Studies, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $u Institute of Physiology and Pathophysiology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0000000297710468 $7 xx0128793
773    0_
$w MED00165795 $t Therapeutics and clinical risk management $x 1176-6336 $g Roč. 20 (20240910), s. 611-618
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39280635 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241008 $b ABA008
991    __
$a 20241016081844 $b ABA008
999    __
$a ok $b bmc $g 2196388 $s 1229801
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 20 $c - $d 611-618 $e 20240910 $i 1176-6336 $m Therapeutics and clinical risk management $n Ther Clin Risk Manag $x MED00165795
LZP    __
$a Pubmed-20241008

Find record

Citation metrics

Archiving options